The latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.
Mukhtar Ahmed
Advertisement
Mukhtar Ahmed is Vice President, Product Strategy, Oracle Health Sciences.
Articles by Mukhtar Ahmed
Mukhtaer Ahmed outlines how advances in machine-to-machine (M2M) technologies have the potential to transform clinical development programs, including clinical trials.
Advertisement
Latest Updated Articles
- The Future is Now: Leveraging Machine-to-Machine Technology to Advance Clinical Trials
Published: October 22nd 2013 | Updated:
- Risk-Based Monitoring: From the Road Less Traveled to Productivity Superhighway
Published: February 24th 2014 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
5
